Role of Extracellular Vesicles in Influenza Virus Infection

Jiang, Yuan; Cai, Xiaowen; Yao, Jiwen; Guo, Huanhuan; Liang, Yin; Leung, Albert Wingnang; Xu, Chuanshan

doi:10.3389/fcimb.2020.00366

Cited by 18 publications

(13 citation statements)

References 90 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study, SARS-CoV-2–induced EVs are suggested to be a potential vaccine solution for viral infections [ 42 , 43 ]. Published reports indicate that EVs derived from stem cells (after being transfected by DNA vectors that express Nef mutant/Influenza virus A-NP) could induce cytotoxic T cell response potent enough to kill large antigenic peptide load in mice models, making exosomes a suitable alternate vaccination solution [ 44 , 45 ]. Time course and antibody development of coronavirus is shown in Fig.…”

Section: Extracellular Vesicles and Vaccine Developmentmentioning

confidence: 99%

Exploring the utility of extracellular vesicles in ameliorating viral infection-associated inflammation, cytokine storm and tissue damage

Pillalamarri¹,

Abdullah²,

Khan³

et al. 2021

Translational Oncology

View full text Add to dashboard Cite

Extracellular vesicles (EVs) have emerged as potential mediators of intercellular communication. EVs are nano-sized, lipid membrane–bound vesicles that contains biological information in the form of proteins, metabolites and/or nucleic acids. EVs are key regulators of tissue repair mechanisms, such as in the context of lung injuries. Recent studies suggest that EVs have the ability to repair COVID19-associated acute lung damage. EVs hold great promise for therapeutic treatments, particularly in treating a potentially fatal autoimmune response and attenuate inflammation. They are known to boost lung immunity and are involved in the pathogenesis of various lung diseases, including viral infection. EV-based immunization technology has been proven to elicit robust immune responses in many models of infectious disease, including COVID-19. The field of EV research has tremendous potential in advancing our understanding about viral infection pathogenesis, and can be translated into anti-viral therapeutic strategies.

show abstract

Section: Extracellular Vesicles and Vaccine Developmentmentioning

confidence: 99%

Exploring the utility of extracellular vesicles in ameliorating viral infection-associated inflammation, cytokine storm and tissue damage

Pillalamarri¹,

Abdullah²,

Khan³

et al. 2021

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…Influenza virus infection is another example of a healthcare concern that causes significant morbidity and mortality worldwide (150). Despite the wide variety of vaccine types available for influenza infection, studies have shown that exosomes can be used as a new platform for designing influenza vaccines, with exhibition of advantages over classical vaccines (151,152). For example, airway exosomes released during influenza virus infection can carry host proteins with anti-influenza properties and can help trigger immune responses (153).…”

Section: Exosome-based Vaccines For Treatment Of Viral Infectious Diseasesmentioning

confidence: 99%

Exosome-Based Vaccines: History, Current State, and Clinical Trials

2021

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are released by most cell types as part of an intracellular communication system in crucial processes such as inflammation, cell proliferation, and immune response. However, EVs have also been implicated in the pathogenesis of several diseases, such as cancer and numerous infectious diseases. An important feature of EVs is their ability to deliver a wide range of molecules to nearby targets or over long distances, which allows the mediation of different biological functions. This delivery mechanism can be utilized for the development of therapeutic strategies, such as vaccination. Here, we have highlighted several studies from a historical perspective, with respect to current investigations on EV-based vaccines. For example, vaccines based on exosomes derived from dendritic cells proved to be simpler in terms of management and cost-effectiveness than dendritic cell vaccines. Recent evidence suggests that EVs derived from cancer cells can be leveraged for therapeutics to induce strong anti-tumor immune responses. Moreover, EV-based vaccines have shown exciting and promising results against different types of infectious diseases. We have also summarized the results obtained from completed clinical trials conducted on the usage of exosome-based vaccines in the treatment of cancer, and more recently, coronavirus disease.

show abstract

“…Although classical vaccine approaches have demonstrated efficacy in controlling viral disease outbreaks, 63 they are known to have limited protective immunity and efficacy when exposed to new viral strains. 64,65 During the COVID-19 pandemic, a new type of vaccine based on a nucleosidemodified mRNA encoding part of the SARS-CoV-2 spike protein has been released. This mRNA-based vaccine triggers an immune response against infection by the virus protein, with high efficacy.…”

Section: Prevention: the Role Of Exosomes In Covid-19 Vaccinesmentioning

confidence: 99%

The Role of Exosomes in the Treatment, Prevention, Diagnosis, and Pathogenesis of COVID-19

et al. 2021

View full text Add to dashboard Cite

The novel coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), continues to be a major health concern. In search for novel treatment strategies against COVID-19, exosomes have attracted the attention of scientists and pharmaceutical companies worldwide. Exosomes are small extracellular vesicles, secreted by all types of cells, and considered as key mediators of intercellular communication and stem-cell paracrine signaling. Herein, we reviewed the most recent literature about the role of exosomes as potential agents for treatment, prevention, diagnosis, and pathogenesis of COVID-19. Several studies and ongoing clinical trials have been investigating the anti-inflammatory, immunomodulatory, and reparative effects of exosomes derived from mesenchymal stem/stromal cells for COVID-19-related acute lung injury. Other studies reported that exosomes play a key role in convalescent plasma therapy for COVID-19, and that they could be of use for the treatment of COVID-19 Kawasaki's-like multisystem inflammatory syndrome and as drug delivery nanocarriers for antiviral therapy. Harnessing some advantageous aspects of exosome biology, such as their endogenous origin, capability of crossing biological barriers, high stability in circulation, and low toxicity and immunogenicity, several companies have been testing exosome-based vaccines against SARS-CoV-2. As they carry cargos that mimic the status of parent cells, exosomes can be isolated from a variety of sources, including plasma, and employed as biomarkers of COVID-19. Lastly, there is growing evidence supporting the role of exosomes in COVID-19 infection, spread, reactivation, and reinfection. The lessons learned using exosomes for COVID-19 will help determine their efficacy and applicability in other clinical conditions.

show abstract

Role of Extracellular Vesicles in Influenza Virus Infection

Cited by 18 publications

References 90 publications

Exploring the utility of extracellular vesicles in ameliorating viral infection-associated inflammation, cytokine storm and tissue damage

Exploring the utility of extracellular vesicles in ameliorating viral infection-associated inflammation, cytokine storm and tissue damage

Exosome-Based Vaccines: History, Current State, and Clinical Trials

The Role of Exosomes in the Treatment, Prevention, Diagnosis, and Pathogenesis of COVID-19

Contact Info

Product

Resources

About